MAIA Biotechnology, Inc.
MAIA evidence brief
What we can confirm
- BioSniper Score:
- 9.1 / 10
- Market Cap:
- $79.1M
- Lead Asset:
- angiomax rtu (Approved)
What it means
What to watch
Prepared research question
What matters most for MAIA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MAIA
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, with its lead asset ateganosine (THIO) being investigated in Phase 2 and Phase 3 trials for non-small cell lung cancer and other solid tumors.
Key risk: Cash depletion risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$79.1M
Cash Runway
—
Lead Asset
angiomax rtu (Approved)Next Catalyst
Patent_Expiry · Apr 20, 2038Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 3 clinical trials · 3 catalysts · 10 FDA decisions for MAIA Biotechnology, Inc..
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, with its lead asset ateganosine (THIO) being investigated in Phase 2 and Phase 3 trials for non-small cell lung cancer and other solid tumors.
- MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, with lead asset ateganosine (THIO) [sec · filed 2026-08-21].
- As of 2026-06-30, the company reported cash & equivalents of $0.0M, net income of -$7.9M, and shareholders' equity of $20.7M [sec].
- Phase 2 clinical trials in HCC, CRC, and SCLC are planned to be initiated in 2026, evaluating ateganosine sequenced with tislelizumab [sec · filed 2026-08-21].
- In April 2026, the first U.S. clinical site was activated for the Phase 2 THIO-101 expansion trial in third-line NSCLC, with plans for four additional U.S. sites in 2026 [sec_mda · as of 2026-05-11].
- A clinical master supply agreement with Roche was announced in June 2025 for future studies combining ateganosine with atezolizumab [sec · filed 2026-08-21].
What works
- The company has established multiple clinical collaborations, including a master supply agreement with Roche and a partnership with BeOne for tislelizumab, expanding its combination study pipeline [sec · filed 2026-08-21].
- MAIA has initiated a Phase 3 study of ateganosine sequenced with cemiplimab in advanced/metastatic NSCLC, indicating progression to later-stage trials [catalyst].
- The company raised $30 million in a public offering in March 2026, providing capital to support ongoing clinical programs [sec_mda · as of 2026-08-10].
What to weigh
- As of 2026-06-30, the company reported zero cash & equivalents and a net loss of $7.9M, indicating a need for further financing to sustain operations [sec].
- All product candidates are in clinical stages with no approved products, meaning no revenue from product sales and reliance on external funding [sec · filed 2026-08-21].
- The company faces typical clinical-stage risks, including uncertain trial outcomes, regulatory hurdles, and competition in the oncology space [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer.
“We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer.”
SEC filings · August 21, 2026
Ateganosine is the lead asset with a dual mechanism of action.
“Ateganosine (also known as THIO, 6-thio-dG or 6-thio-2 '-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.”
SEC filings · August 21, 2026
First U.S. clinical site activated for Phase 2 THIO-101 expansion trial in NSCLC.
“On April 16, 2026, we announced the activation the first U.S. clinical site in its Phase 2 THIO-101 expansion trial of its lead investigational therapy as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).”
SEC MD&A · May 11, 2026
MAIA raised $30 million in a public offering in March 2026.
“On March 4, 2026, we issued and sold 20,000,000 shares of our common stock in confidentially marketed public offering at a price of $1.50 per share for aggregate gross proceeds of $30 million”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2038-04-20 · Patent_Expiry · SINCALIDE — Patent expiry for NDA210850; no direct impact on MAIA's pipeline as it is not related to ateganosine.
- 2039-05-20 · Patent_Expiry · BIVALIRUDIN — Patent expiry for NDA211215; not related to MAIA's core programs.
- 2042-09-23 · Patent_Expiry · BORTEZOMIB — Patent expiry for NDA215331; not related to MAIA's pipeline.
Risks & what to watch (3)›
Key risks
- Cash depletion risk — Cash & equivalents were $0.0M as of 2026-06-30, requiring near-term financing to continue operations [sec].
- No approved products — All candidates are in clinical stages; no revenue from product sales, relying on external funding [sec · filed 2026-08-21].
- Clinical trial uncertainty — Phase 2 and Phase 3 outcomes are uncertain; failure could materially impact the company's prospects [sec_mda · as of 2026-08-10].
What to watch
- Initiation of Phase 2 trials in HCC, CRC, and SCLC in 2026, evaluating ateganosine with tislelizumab [sec · filed 2026-08-21].
- Progress of the Phase 2 THIO-101 expansion trial in NSCLC, including U.S. site activations and enrollment [sec_mda · as of 2026-05-11].
- Further financing or partnership announcements given the zero cash position as of 2026-06-30 [sec].
- Updates from the Phase 3 study of ateganosine with cemiplimab in NSCLC [catalyst].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run MAIA Biotechnology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MAIA Biotechnology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.37 · 0% dilution
Lead: Approved
7 candidates
3 upcoming, next in ~4206d
6 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 4.1%
- Days to cover
- 1.9
- Shares short
- 2,304,530
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MAIA short interestGovernance
Frequently asked questions
What is the AI investment thesis for MAIA Biotechnology, Inc.?
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, with its lead asset ateganosine (THIO) being investigated in Phase 2 and Phase 3 trials for non-small cell lung cancer and other solid tumors.
What is MAIA Biotechnology, Inc.'s lead drug candidate?
MAIA Biotechnology, Inc.'s most advanced tracked candidate is angiomax rtu (Approved).
What is MAIA Biotechnology, Inc.'s next catalyst?
MAIA Biotechnology, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA210850" — expected April 20, 2038.
Who is the CEO of MAIA Biotechnology, Inc.?
Dr. Vlad Vitoc M.B.A., M.D. is the chief executive officer of MAIA Biotechnology, Inc. (MAIA).
Where is MAIA Biotechnology, Inc. headquartered?
MAIA Biotechnology, Inc. (MAIA) is headquartered in Chicago, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.